Patients With a Single, Small (2 cm or Less) Cancer Nodule in the Thyroid Gland Will be Offered Active Surveillance Initially for 5 Years. In Case of Cancer Growth or Changes in Ultrasonographic Appearance, Further Treatment Will be Offered.

Active Surveillance of Small Thyroid Cancers.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07822217

Enrollment

Registered

2026-09-16

Start date

2026-03-01

Completion date

2034-02-28

Last updated

2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Surveillance, Thyroid Cancer

Brief summary

Patients with a single, small (less than 2 cm) cancer nodule in the thyroid gland will be offered active surveillance initially for 5 years. In case of cancer growth or changes in ultrasonographic appearance, further treatment will be offered.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* age of 30 years or older AND * single, well-defined tumor in the thyroid gland, with a FNAB suspicious of cancer or diagnostic of cancer (category V or VI in the Bethesda system) AND * tumor size of 2 cm or less in all dimensions.

Exclusion criteria

* suspicion of disseminated disease because of: * PET-positive lymph nodes on the neck * suspicious lymph-nodes by neck ultrasonography (US) * signs of capsular invasion of the tumor * suspicion of metastatic disease due to findings on PET-CT-scan or thoracic CT-scan; OR * tumor placement at a high-risk location (in the thyroid capsule or near the trachea) OR * previous thyroid surgery OR * concomitant hyperparathyroidism (ionized calcium \> 1.32 mmol/L and PTH \> 6 pmol/L) OR * if the patient is pregnant OR * If the patient is unable to give informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Treatment	24 months	The need for treatment due to tumor growth within 24 months (cumulative incidence)

Countries

Denmark

Outcome results